A Potential Shift In FDA's Approach To Drug Trial Design
By Jessica Ritsick, Yifan Wang and Barbara Jones-Binns · February 19, 2026, 5:54 PM EST
On Jan. 9, the U.S. Food and Drug Administration issued draft guidance clarifying how Bayesian approaches may be used in clinical trials to support regulatory decision-making. It reflects the agency's continued...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login